SARS-CoV-2 Spike RBD Recombinant Nanobody
Beta LifeScience
SKU/CAT #: BLC-06436A
The Binding Activity of SARS-CoV-2 Spike RBD Nanobody with SARS-CoV-2-S1-RBD | Activity: Measured by its binding ability in a functional ELISA. Immobilized SARS-CoV-2-S1-RBD (the antibody at 2 μg/ml can bind SARS-CoV-2 Spike RBD Nanobody, the EC50 is 0.8674 ng/ml.
In the Colloidal Gold Immunochromatography Assay detection system, the background of antibody (SARS-CoV-2 Spike RBD Recombinant Nanobody) is clean, the detection limit can be as low as 25ng/ml (1.75ng/0.07ml), and the sensitivity is very good.
SARS-CoV-2 Spike RBD Nanobody (SARS-CoV-2 Spike RBD Recombinant Nanobody) competed with ACE2-HRP conjugate (the antibody for binding to SARS-CoV-2-S1-RBD (the antibody The binding signal of SARS-CoV-2-S1-RBD and ACE2-HRP conjugate was gradually reduced as the SARS-CoV-2 Spike RBD Nanobody concentrations increased. It indicated that this SARS-CoV-2 Spike RBD Nanobody effectively inhibited the SARS-CoV-2-S1-RBD/ACE2 binding. And the IC50 of this SARS-CoV-2 Spike RBD Nanobody is 1.296 nM.
SARS-CoV-2 Spike RBD Recombinant Nanobody
Beta LifeScience
SKU/CAT #: BLC-06436A
Our products are highly customizable to meet your specific needs. You can choose options such as endotoxin removal, liquid or lyophilized forms, preferred tags, and the desired functional sequence range for proteins. Submitting a written inquiry expedites the quoting process.
Product Overview
| Product Title | SARS-CoV-2 Spike RBD Recombinant Nanobody |
| Description | The recombinant antibody against S (Spike glycoprotein) was produced using the Recombinant Human Novel Coronavirus Spike glycoprotein(S) (319-541aa) as the immunogen. This antibody exists as a non-conjugated isotype VHH fusion with human IgG1 Fc, Affinity-chromatography purified. This antibody has been validated on ELISA, GICA, Neutralising. |
| Uniprot Id - Alink | P0DTC2 |
| Reactivity | Human Novel Coronavirus (SARS-CoV-2/ 2019-nCoV) |
| Target Name | S (Spike glycoprotein) |
| Target Synonyms | S; 2; Spike glycoprotein; S glycoprotein; E2; Peplomer protein) |
| Immunogen Description | Recombinant Human Novel Coronavirus Spike glycoprotein(S) (319-541aa) |
| Immunogen Species | Human Novel Coronavirus (SARS-CoV-2/ 2019-nCoV) |
| Immunogen Sequence | Complete sequences for the immunogen, target protein, and peptides are available upon request. |
| Conjugate | Non-conjugated |
| Clonality | Monoclonal |
| Isotype | VHH fusion with human IgG1 Fc |
| Purification Method | Affinity-chromatography purified |
| Buffer | 0.03% Proclin 300Constituents: 50% Glycerol, 0.01M PBS, pH 7.4 |
| Form | Liquid |
| Application | ELISA, GICA, Neutralising |
| Storage Conditions | Upon receipt, store at -20°C or -80°C. Avoid repeated freeze. |
